MedTrace Logo

VIBRANT: VIB4920 for Active Lupus Nephritis

NCT05201469 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-12-19

No results posted yet for this study

Summary

This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

Conditions

Interventions

DRUG

VIB4920

Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone

DRUG

Placebo for VIB4920

Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Maria Dall'Era, M.D. · University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center

  • Betty Diamond, M.D. · Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases

  • David Wofsy, M.D. · University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-16
Primary Completion
2026-08-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05201469 on ClinicalTrials.gov